We further examined the inhibitory effect of the combination of PF (50 μmol/L) and erlotinib (5 μmol/L) on high ErbB3-expressing pancreatic cancer cell lines BxPC-3(Fig. 1B) and L3.6pl (Fig. 1C) using Trypan Blue Exclusion and MTS assays. This evidence concerns the gene ERBB3 and familial pancreatic carcinoma.